The curious morphology and orientation of Orion proplyd HST-10

HST-10 is one of the largest proplyds in the Orion Nebula and is located approximately 1' SE of the Trapezium. Unlike other proplyds in Orion, however, the long-axis of HST-10 does not align with theta 1 C Ori, but is instead aligned with the rotational axis of the HST-10 disk. This cannot be easily explained using current photo-evaporation models. In this letter, we present high spatial resolution near-infrared images of the Orion proplyd HST-10 using Keck/NIRC2 with the Laser Guide Star Adaptive Optics system, along with multi-epoch analysis of HH objects near HST-10 using Hubble Space Telescope WFPC2 and ACS cameras. Our narrow-band near-IR images resolve the proplyd ionization front (IF) and circumstellar disk down to 23 AU at the distance to Orion in Br gamma, He I, H_2, and PAH emission. Br gamma and He I emission primarily trace the IF (with the disk showing prominently in silhouette), while the H_2 and PAH emission trace the surface of the disk itself. PAH emission also traces small dust grains within the proplyd envelope which is asymmetric and does not coincide with the IF. The curious morphology of the PAH emission may be due to UV-heating by both theta 1C Ori and theta 2A Ori. Multi-epoch HST images of the HST-10 field show proper motion of 3 knots associated with HH 517, clearly indicating that HST-10 has a jet. We postulate that the orientation of HST-10 is determined by the combined ram-pressure of this jet and the FUV-powered photo-ablation flow from the disk surface.Comment: 12 pages, 2 figures. Accepted for publication in ApJ Letters, 4 Nov 201

Thermal Dust Emission from Proplyds, Unresolved Disks, and Shocks in the Orion Nebula

We present a new 11.7 micron mosaic image of the Orion nebula obtained with T-ReCS on Gemini South. The map includes the BN/KL region, the Trapezium, and OMC-1 South. Excluding BN/KL, we detect 91 point sources, with 27 known proplyds and over 30 ``naked'' stars showing no extended structure in HST images. Within the region we surveyed, 80 percent of known proplyds show detectable emission, almost 40 percent of naked stars are detected at 11.7 micron, and the fraction of all visible sources with IR excess emission is roughly 50 percent. Thermal dust emission from stars with no extended structure in HST images means that they have dust disks comparable to the size of our solar system. Proplyds and stars with IR excess show a clear anti-correlation in their spatial distribution, with proplyds clustered close to theta1C, and other infrared sources found farther away. We suspect that the clustered proplyds trace the youngest 0.5 Myr age group associated with the Trapezium, while the more uniformly-distributed sources trace the older 1-2 Myr population of the ONC. This suggests that small disks persist for a few Myr in irradiated environments, and hints that hierarchical sub-clustering has been important. Within 30 arcsec of theta1C, all proplyds are detected at 11.7 micron. The star theta1D is associated with the most prominent mid-IR dust arc in the nebula. We propose that this arc is the consequence of theta1D being the closest member of the Trapezium to the background cloud. Finally, we detect dust emission from HH jets in Orion, including HH202, HH529, HH513, and HH514. This is the first detection of mid-IR continuum emission from dust in the body of a collimated HH jet or bow shock.Comment: accepted by AJ. 27 pages, 11 figs, 4 color figs. If you actually want to see the figures, download this version: ftp://origins.colorado.edu/pub/nathans/smith.trecs.pd

Randomized, double-blind, placebo-controlled crossover trial of once daily empagliflozin 25 mg for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass.

Aims To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass (RYGB). Methods Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed meal tolerance test (MMTT). Outcomes of the outpatient period were assessed using continuous glucose monitoring (CGM) and an event-tracking app. Results The amplitude of glucose excursion during the MMTT was 8.1±2.4 mmol/L with empagliflozin vs 8.1±2.6 mmol/L with placebo (mean±SD, p=0.807). CGM-based mean amplitude of glucose excursion (MAGE) during the 20 day-period was lower with empagliflozin than placebo (4.8±1.3 vs 5.2±1.6. p=0.028). Empagliflozin reduced the time spent with CGM values >10.0 mmol/L (3.8±3.5 % vs. 4.7±3.8 %, p =0.009), but not the time spent with CGM values <3.0 mmol/L (1.7±1.6 % vs. 1.5±1.5 %, p=0.457). No significant difference was observed in the quantity and quality of recorded symptoms. Eleven adverse events occurred with empagliflozin (three drug-related) and six with placebo. Conclusions Empagliflozin 25 mg reduces glucose excursions but not hypoglycaemia in individuals with PBH

Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Aims: To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB). Methods: Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed-meal tolerance test (MMTT). Outcomes of the outpatient period were assessed using continuous glucose monitoring (CGM) and an event-tracking app. Results: The amplitude of glucose excursion during the MMTT was 8.1 ± 2.4 mmol/L with empagliflozin versus 8.1 ± 2.6 mmol/L with placebo (mean ± standard deviation, P = 0.807). CGM-based mean amplitude of glucose excursion during the 20-day period was lower with empagliflozin than placebo (4.8 ± 1.3 vs. 5.2 ± 1.6. P = 0.028). Empagliflozin reduced the time spent with CGM values >10.0 mmol/L (3.8 ± 3.5% vs. 4.7 ± 3.8%, P = 0.009), but not the time spent with CGM values <3.0 mmol/L (1.7 ± 1.6% vs. 1.5 ± 1.5%, P = 0.457). No significant difference was observed in the quantity and quality of recorded symptoms. Eleven adverse events occurred with empagliflozin (three drug-related) and six with placebo. Conclusions: Empagliflozin 25 mg reduces glucose excursions but not hypoglycemia in individuals with PBH

ERRATUM: "AN X-RAYS SURVEY OF THE YOUNG STELLAR POPULATION OF THE LYNDS 1641 AND IOTA ORIONIS REGIONS" (2013, ApJ, 768, 99)

I. Pillitteri1, S. J. Wolk1, S. T. Megeath2, L. Allen3, J. Bally4, Marc Gagne5, R. A. Gutermuth6, L. Hartman7, G. Micela8, P. Myers1, J. M. Oliveira9, S. Sciortino8, F. Walter1, L. Rebull10, and J. Stauffer10 1 SAO–Harvard Center for Astrophysics, 60 Garden St, Cambridge MA 02138, USA; [email protected] 2 Department of Physics & Astronomy, University of Toledo, OH, USA 3 National Optical Astronomy Observatory, USA 4 University of Colorado, Boulder, CO, USA 5 Department of Geology & Astronomy, West Chester University, West Chester, PA, USA 6 Department of Astronomy, University of Massachusetts, Amherst, MA 01003, USA 7 University of Michigan, Ann Arbor, MI, USA 8 INAF Osservatorio Astronomico di Palermo, Italy 9 School of Physical & Geographical Sciences, Lennard-Jones Laboratories, Keele University, Staffordshire ST5 5BG, UK 10 CALTECH, Pasadena, CA, 91125, USA Received 2013 June 27; published 2013 July 2

Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice

International audienceThe significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past six years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage

Proceedings of Abstracts, School of Physics, Engineering and Computer Science Research Conference 2022

© 2022 The Author(s). This is an open-access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For further details please see https://creativecommons.org/licenses/by/4.0/. Plenary by Prof. Timothy Foat, ‘Indoor dispersion at Dstl and its recent application to COVID-19 transmission’ is © Crown copyright (2022), Dstl. This material is licensed under the terms of the Open Government Licence except where otherwise stated. To view this licence, visit http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected] present proceedings record the abstracts submitted and accepted for presentation at SPECS 2022, the second edition of the School of Physics, Engineering and Computer Science Research Conference that took place online, the 12th April 2022

HAWC+/SOFIA Multiwavelength Polarimetric Observations of OMC-1

We report new polarimetric and photometric maps of the massive star-forming region OMC-1 using the HAWC+ instrument on the Stratospheric Observatory for Infrared Astronomy. We present continuum polarimetric and photometric measurements of this region at 53, 89, 154, and 214 μm at angular resolutions of 5'', 8'', 14'', and 19'' for the four bands, respectively. The photometric maps enable the computation of improved spectral energy distributions for the region. We find that at the longer wavelengths, the inferred magnetic field configuration matches the "hourglass" configuration seen in previous studies, indicating magnetically regulated star formation. The field morphology differs at the shorter wavelengths. The magnetic field inferred at these wavelengths traces the bipolar structure of the explosive Becklin–Neugebauer/Kleinman–Low outflow emerging from OMC-1 behind the Orion Nebula. Using statistical methods to estimate the field strength in the region, we find that the explosion dominates the magnetic field near the center of the feature. Farther out, the magnetic field is close to energetic equilibrium with the ejecta and may be providing confinement to the explosion. The correlation between polarization fraction and the local polarization angle dispersion indicates that the depolarization as a function of unpolarized intensity is a result of intrinsic field geometry as opposed to decreases in grain alignment efficiency in denser regions